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To improve quality of care, centralisation of cancer services in high-volume centres has
been stimulated. Studies linking specialisation and high (surgical) volumes to better out-
comes already appeared in the 1990’s. However, actual centralisation was a difficult pro-
cess in many countries. In this study, factors influencing the centralisation of cancer
services in the Netherlands were determined.
Material and methods
Centralisation patterns were studied for three types of cancer that are known to benefit from
high surgical caseloads: oesophagus-, pancreas- and bladder cancer. The Netherlands Can-
cer Registry provided data on tumour and treatment characteristics from 2000–2013 for
respectively 8037, 4747 and 6362 patients receiving surgery. By plotting timelines of centrali-
sation of cancer surgery, relations with the appearance of (inter)national scientific evidence,
actions of medical specialist societies, specific regulation and other important factors on the
degree of centralisation were ascertained.
Results
For oesophagus and pancreas cancer, a gradual increase in centralisation of surgery is
seen from 2005 and 2006 onwards following (inter)national scientific evidence. Centralisa-
tion steps for bladder cancer surgery can be seen in 2010 and 2013 anticipating on the publi-
cation of norms by the professional society. The most influential stimulus seems to have
been regulations on minimum volumes.
Conclusion
Scientific evidence on the relationship between volume and outcome lead to the start of cen-
tralisation of surgical cancer care in the Netherlands. Once a body of evidence has been
established on organisational change that influences professional practice, in addition some
form of regulation is needed to ensure widespread implementation.
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Introduction
Centralisation of low volume cancers and high-risk surgical procedures is a frequently studied
organisational quality issue, especially in surgical oncology. The first volume-outcome rela-
tionship in surgery was described in 1979 by Luft et al.[1] In the following decades numerous
studies have addressed the question whether higher surgical volumes result in an increased
quality of care.[2] Many of these studies concerned cancer surgery and a large body of evi-
dence developed in favour of centralisation of surgical procedures such as pancreatectomies
and oesophagectomies.[3] In general, a higher volume of surgery is associated with lower post-
operative mortality and morbidity.[2, 4, 5] Nevertheless, in the Netherlands, referral patterns
for pancreatic and oesophageal cancer remained largely unchanged up to the early 2000’s,
despite a lively debate on the introduction of minimum surgical volumes.[6]
There may be several reasons why centralisation was not directly embraced as a method to
improve cancer care. The quality of the scientific evidence was questioned as many early stud-
ies were observational and not hypothesis driven and few studies actually investigated quality
improvement after centralisation.[5] Possible differences in case-mix restricted the generalisa-
bility of the available scientific evidence to the Dutch healthcare situation (as most studies
were performed in the Unites States). As with any new treatment or technology there is a diffu-
sion period before it becomes widely implemented. For example, a Dutch study on the dissem-
ination of the sentinel node biopsy in breast cancer revealed a gradual increase over the course
of 5 years (1998–2003).[7] There is still debate on volume thresholds, ceiling effects and the
exact mechanisms through which quality is improved, though at present only a few question
the need to centralise low volume and high-risk or complex procedures. Centralisation of ser-
vices is a delicate issue as professional pride and material interests could play a role in the
debate and consequent decisions.
The first Dutch scientific evidence for a positive volume-outcome relationship in pancreas and
oesophagus surgery was published by Gouma et al. in 1997 & 2000 and by van Lanschot et al. in
2001.[8–10] Wouters et al. showed reduced postoperative morbidity and mortality after centralis-
ing oesophageal resections between 2000–2004.[11] In 2003, the Dutch Healthcare inspectorate
started a new supervision policy based on publicly reported quality indicators including total
number of surgeries for low volume tumours.[12] The first form of regulation started in 2006
when the Healthcare Inspectorate (IGZ) banned oesophageal resections from hospitals with an
annual surgical volume lower than 10. This number was also advised for pancreatic resections but
not officially regulated. In 2010 the “quality of cancer care” report was published by the Dutch
Cancer Society.[13] In this report, centralisation of low volume tumours and high-risk procedures
was regarded to be one of the main strategies to reduce variation in outcome. The Healthcare
Inspectorate insisted that in 2011 all medical specialists societies published minimum volume
standards (insisting on minimum volumes of 20 operations per year) for highly complicated pro-
cedures and regulation would follow from 2013 onwards. In 2011 the Association of Surgeons in
the Netherlands (ASN) increased the minimum annual number of low volume, high-risk opera-
tions to 20. In 2012, the Dutch Federation of Oncological Societies (in Dutch: SONCOS, consist-
ing of the Dutch Associations for Surgical Oncology (NVCO), Medical Oncology (NVMO) and
Radiotherapy and Oncology (NVRO)) set minimum volume standards for the treatment of sev-
eral types of cancer.[14] In recent years, insurance companies started to use these thresholds for
contracting policies adding an extra stimulus to the centralisation debate.
It is unknown whether and which professional, organisational and regulatory stimuli are
most effective in stimulating centralisation. Studying this might also provide a more general
insight in what drives quality related organisational change in cancer care. We performed a
nationwide analysis on the centralisation of oesophagus, pancreas and bladder cancer surgery.
Centralisation of cancer treatment
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Oesophagus and pancreas cancer are the most studied types of cancer in relation to the volume
of surgery. Bladder cancer is likely to benefit from centralisation but minimum thresholds
were not established in the Netherlands until 2010.[15–18] We hypothesise that even though
centralisation of surgery will occur voluntarily and gradually based on scientific evidence, the
most important factor for widespread centralisation is official regulation.
Materials and methods
Population
Data on all patients that were diagnosed with oesophagus, pancreas and bladder cancer in The
Netherlands between January 1st 2000 and December 31st 2013 were retrieved from the Neth-
erlands Cancer Registry (NCR). The NCR contains patient, tumour and (hospital of) treatment
data of every newly diagnosed cancer patient. Topography and morphology is coded according
to the International Classification of Diseases for Oncology (ICD-O) and staging according to
the TNM-classification. Quality of the data is high and completeness is estimated to be at least
95%.[19, 20] The total number of inhabitants of The Netherlands was 15.9 million in 2000 and
16.8 million in 2013.[21]
We included patients with oesophagus tumours including cardia (C15.0–15.9, C16.0),
pancreas and peri-ampullary tumours (C25.0–25.9, C24.1, C17.0) and bladder tumours
(C67.0–67.9). Exclusion criteria were: unknown hospital of surgery or diagnosis at autopsy.
Per tumour the total annual surgical volume was calculated per hospital. In the NCR the
type of surgery was not completely specified before 2005. Different types of surgery could
have been coded under a non-specified surgical code; patients with the same treatment code
could have had a pancreaticoduodenectomy or only local treatment. We accepted this for
oesophagus and pancreas cancer because local surgical treatment was not common practice
then. From 2005 we were able to differentiate oesophagus(cardia) resections and pancrea-
tectomies. We included all types of surgery for pancreas malignancies, not only (pylorus
preserving) pancreaticoduodenectomies, but also pancreas tail resections. Local surgical
treatment is more common in bladder cancer, therefore the centralisation of cystectomies is
studied from 2005 onwards. Only the initial treatment (within six months after diagnosis)
for every new bladder tumour was registered, thereby disregarding cystectomy for an initial
non muscle-invasive tumour that progressed to muscle-invasive disease more than six
months after the first diagnosis and a salvage cystectomy after radiotherapy. When the ini-
tial treatment took more than six months to complete, e.g. in case neo-adjuvant chemother-
apy, the cystectomy was registered.
Analyses
Hospitals were categorised based on the surgery volume per tumour per year:<10, 10–19 and
20. These categories were chosen based on the first minimum annual thresholds of 10 which
later changed to 20. If the year of surgery was unknown the year of incidence was used. Time-
lines with the proportion of patients per hospital category were plotted from 2000–2013
(cystectomies from 2005–2013) with descriptions of important influencing factors including
landmark studies, regulation, and guidelines by specialists societies. STATA version 12.0 was
used for the main analyses. Trendbreak was analysed using Joinpoint Software. Because the
minimum surgical volume for pancreas and oesophagus cancer was 10 until 2011 and still is
10 for cystectomies we analysed trendbreak for minimum annual volumes of 10 (including the
10 and20 category).
Centralisation of cancer treatment
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Results
The study population is presented in Table 1. The high number of patients with bladder cancer
can be explained by the high numbers of carcinoma in situ. Fig 1 shows an increasing number
of surgical procedures for oesophagus, pancreas and bladder cancer.
Oesophagus cancer
The total number of operations per year gradually increased from 387 in 2000 to 690 in 2013
(Fig 1). Initially, the rise in absolute volume was not represented in the volume categories (Fig
2). Trendbreak analysis was significant in 2005 and a strong rise can be seen in the20 cate-
gory from 2006 onwards. In the period before 2006, the rising number of patients was distrib-
uted among all three volume categories while the rise in incidence after 2006 contributed
foremost to the>20 surgeries per year category. This is represented by the total number of
hospitals that performed oesophagus surgery. This varied from 55 in 2000 to 64 in 2004 and 55
in 2006. A sharp decrease was then seen in the period from 2011–2013; in 2011 there were still
43 hospitals performing oesophagus surgery, which dropped to 27 in 2013. The trendbreak in
2006 coincides with the execution of a Dutch prospective study from 2000–2004 which was
published in 2009 but reported upon in national fora earlier and the new minimum threshold
for oesophageal resections that was set on 10 per year by the Healthcare Inspectorate in 2006.
[11]. In 2013 93% of the patients were operated in hospitals that perform 20 or more surgeries
per year.
Pancreas cancer
Fig 1 shows a sharp increase in the total volume of pancreas surgery, from 174 in 2000 to 621
in 2013. Like in oesophagus surgery, this rise in absolute volume was initially distributed
among all three volume categories, with a steep rise in the 10–20 category between 2004 and
2007. Until 2011 the 0–10 and 10–20 categories remain relatively stable, implying that the
extra influx of patients foremost contributed to the >20 category. The number of hospitals
reflects this observation: in 2000 there were 41 hospitals that performed pancreas surgery, ris-
ing to 47 in 2007 and gradually decreasing to 38 in 2013. This is still a relatively high number
of hospitals which is partially caused by our inclusion of all types of pancreas surgery. When
Table 1. Characteristics of the study population of oesophagus and pancreas cancer (2000–2013) and bladder cancer (2005–2013).
Oesophagus N (%) Pancreas N (%) Bladder N (%)
Total number of patients 29,399 19,630 52,763
Sex
Male 21,557 (73.3) 10,474 (53.36) 40,820 (77.36)
Female 7,842 26.7) 9,156 (46.64) 11,943 (22.64)
Stage
0 296 (1.01) 175 (0.89) 27,539 (52.20)
1 2,683 (9.13) 1,726 (8.79) 10,776 (20.42)
2 3,950 (13.44) 3,950 (20.12) 5,759 (10.91)
3 6,405 (21.79) 2,334 (11.89) 3,125 (5.92)
4 10,899 (37.07) 9,876 (50.31) 4,892 (9.27)
unknown 5,166 (17.58) 1,569 (8.00) 672 (1.27)
Receiving surgery
Yes 8,037 (27.3) 4,747 (24.18) 6,362 (12.06)
No 21,362 (72.7) 14,883 (75.82) 4,6401 (87.94)
https://doi.org/10.1371/journal.pone.0195673.t001
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disregarding partial resections (e.g. pancreas tail resections) and only including classical Whip-
ple’s or PPPD’s the number of hospitals dropped from 39 in 2007 to 25 in 2013. Centralisation
occurred rapidly after an initial trendbreak in 2006 and further intensified from 2011 onwards
(Fig 3). In 2013 almost 90% of the patients were operated in a hospital with a yearly volume of
20 or higher.
Bladder cancer
Fig 4 shows a late onset of centralisation compared to oesophagus and pancreas surgery. No
significant trendbreak was evident. A gradual decrease in the<10 category can be seen from
2009 onwards. A strong increase in centralisation to 20 or more surgeries per year can be seen
in 2013. The absolute volume of surgery increased from 554 in 2005 to 912 in 2013 (Fig 1). In
2005 cystectomies were performed in 85 hospitals, decreasing from 80 in 2009 to 60 in 2013.
Discussion
Our results show that centralisation started in the years following the publication of scientific
evidence from Dutch studies and international reviews. Scientific evidence obviously preludes
centralisation but does not seem sufficient to initiate a widespread effect. Official publication
of minimum standards by the medical specialists societies intensified centralisation, especially
in the years before and after publication. This can be seen in all three tumour types. Because
official regulation sometimes initiated the publication of minimum standards by the specialist
societies and intensified after that, there seemed to be interaction between the two phenome-
non’s though regulation seems to have more impact.
Centralisation of oesophageal resections started in 2006 and from 2008 onwards more than
90% of the patients were treated in hospitals with a surgical volume10 per year. A regional
Fig 1. Total number of oesophagectomies and pancreatectomies from 2000–2013 and cystectomies from 2005–2013 in the Netherlands.
https://doi.org/10.1371/journal.pone.0195673.g001
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prospective study in the Netherlands investigated the effects of centralisation of oesophageal
resections from 2000–2004. Along with a reduction in postoperative morbidity and length of
stay, mortality was shown to fall from 12% to 4% and survival improved significantly. The hos-
pitals with the highest procedural volume showed the biggest improvements in outcome.[11]
The results were shared in national conferences and combined with the growing international
evidence strongly enforced the centralisation of surgery for patients with oesophagus cancer.
Consequently, in 2006 the Dutch Health Inspectorate set the minimum threshold on ten per
year and centralisation followed rapidly. The second rise in concentration can be seen from
2011 onwards when hospitals were required to perform at least 20 resections per year which
resulted in a decreasing proportion of patients treated in a hospital with an average annual vol-
ume between 10–20 (Fig 2). The total number of hospitals performing these surgeries supports
the findings that a ‘true’ centralisation effect was happening, instead of an effect occurring
because of the rising incidence. It seems that a combination of scientific evidence and regula-
tion was needed to implement widespread centralisation. Whether scientific evidence alone
has the same effect is questionable when looking at the centralisation pattern of the other two
tumours. While trendbreak analyses for the centralisation of pancreatic cancer surgery show a
significant increase from 2006 onwards, it took until 2009 for more than 80% of the patients to
be operated in a hospital with an annual volume10. Unlike for oesophagectomies, between
2004 and 2011 no officially regulated minimum threshold for pancreas surgery existed. The
decrease that can be seen in pancreas surgery in hospitals with an annual volume <10 co-oc-
curs with the threat of regulation. It might also have been triggered by the centralisation of
oesophagus surgery. It is likely that professionals regarded pancreas surgery as a logical next
Fig 2. Changes in surgical volumes from 2000–2013: Oesophageal resections and relevant external stimuli. Significant trendbreak in 2005 (for cumulative categories
10 and 20 procedures).
https://doi.org/10.1371/journal.pone.0195673.g002
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step in centralisation. In bladder cancer, the process of centralisation started late compared to
oesophagus and pancreas surgery. A sharp increase in centralisation can be seen in 2009, a
year before the Dutch Society for Urology decided on a minimal annual cystectomy threshold
of 10. This coincided with the quality of cancer care report from the Dutch Cancer Society and
two Dutch studies on the effects of volume on outcomes after cystectomy. De Vries et al. obs-
erved lower post-operative mortality related to higher surgical volumes but this difference
could not reach statistical significance.[22] Goossens et al. found that postoperative mortality
after cystectomy is significantly inversely associated with high-volume providers.[23] Further-
more, a study published in 2012 comprising data from 2000–2008 confirmed the inverse rela-
tionship between hospital volume and mortality and morbidity in the Netherlands. The results
of this study showed that the chance of undergoing cystectomy was significantly higher in
high-volume hospitals. Long-term survival after cystectomy was also higher in high-volume
hospitals.[24] This might explain the increase in centralisation in 2013 together with discus-
sions on the appropriateness of the (low) threshold of 10. In January 2015 a minimum number
of 20 cystectomies per year per hospital was decided upon by the Dutch urological society.[25]
For all three cancers, the impact exerted by healthcare insurers on centralization grew from
2011 onwards when they started to incorporate minimum volume standards in their reim-
bursement negotiations with hospitals. There was a threat that low volume hospitals would not
be reimbursed in the future. This pressured hospitals to re-evaluate their position in the onco-
logical surgical field. However, in our study period, a true ‘negative incentive’ by completely
stopping reimbursements for low volume centres was not yet common practice.
Fig 3. Changes in surgical volumes from 2000–2013: Pancreas resections and relevant external stimuli. Significant trendbreak in 2006 (for cumulative categories10
and 20 procedures).
https://doi.org/10.1371/journal.pone.0195673.g003
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The use of the population based Netherlands Cancer registry as our data source is a major
strength of our study. This allowed us to analyse high volumes of patients over a long time
period. Our study also had some limitations. The Netherlands Cancer Registry did not always
specify the type of surgery or hospital of surgery in the period before 2005. Therefore, patients
that received local surgical tumour treatment instead of extensive surgery can be present in
our analyses for oesophagus and pancreas cancer. Because these therapies are not the primary
treatment options we argue that the effect on our analyses is small. Furthermore, the question
can be raised if any surgical procedure for oesophagus and pancreas cancer should take place
in a high volume hospital anyway. Although the standards are based on malignancies, surgery
for benign conditions is not registered in the NCR which may give an underestimation of the
volume of surgeries in that organ. The impact of excluding patients that were treated in an
unknown hospital of surgery is likely to be small, for oesophagus surgery this accounted for
14% between 2000–2005. Our study focusses on a national level and regional initiatives such as
cooperation between groups of surgeons might also have influenced centralisation. In our
analyses we use hospital volume, not the number of operations per surgeon. It can be argued
that a high number of operations per surgeon is more important than hospital volume. Previ-
ous research was not conclusive on this issue. There are multiple studies reporting on a more
important effect of hospital volume arguing that improving quality depends on multidisciplin-
ary aspects of hospital care rather than solely on intraoperative technique. [26, 27, 28]
Our results show that international scientific evidence was not strong enough to convince
large numbers of physicians to change their daily practice and centralise surgical procedures.
Arguments against the generalisability to the Dutch healthcare situation were weakened by a
growing body of evidence and more importantly, national studies with convincing data.
Fig 4. Changes in surgical volumes from 2005–2013: Cystectomies and relevant external stimuli.
https://doi.org/10.1371/journal.pone.0195673.g004
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Regulation did not start centralisation, but followed scientific evidence and subsequent volun-
tary centralisation. Strong national scientific evidence proved to be needed for acceptance in
the field and in addition, regulation seems necessary to implement widespread centralisation.
In contrast to ‘regular clinical cancer research’ the results of organisational change studies are
likely to be greeted with more scepticism which hinders acceptance and implementation. Stud-
ies with solid designs unravelling the mechanisms of organisational aspects and choices (such
as centralisation) are needed for wider acceptance in the field. In general. it seems inevitable
that once a body of evidence has been established on organisational change that influences
professional practice, some form of regulation needs to be added to ensure widespread
implementation.
Acknowledgments
The authors thank the registration teams of the Comprehensive Cancer Organisation Nether-
lands for the collection of data for the Netherlands Cancer Registry and the scientific staff of
the Comprehensive Cancer Organisation Netherlands.
Author Contributions
Conceptualization: Melvin J. Kilsdonk, Sabine Siesling, Michel W. Wouters, Wim H. van
Harten.
Data curation: Melvin J. Kilsdonk, Boukje A. C. van Dijk.
Formal analysis: Melvin J. Kilsdonk, Boukje A. C. van Dijk, Wim H. van Harten.
Investigation: Melvin J. Kilsdonk.
Methodology: Melvin J. Kilsdonk, Sabine Siesling, Boukje A. C. van Dijk, Wim H. van
Harten.
Project administration: Melvin J. Kilsdonk.
Supervision: Sabine Siesling, Boukje A. C. van Dijk, Michel W. Wouters, Wim H. van Harten.
Writing – original draft: Melvin J. Kilsdonk, Sabine Siesling, Wim H. van Harten.
Writing – review & editing: Melvin J. Kilsdonk, Sabine Siesling, Michel W. Wouters, Wim H.
van Harten.
References
1. Luft HS, Bunker JP, Enthoven AC. Should operations be regionalized? The empirical relation between
surgical volume and mortality. N Engl J Med. 1979; 301(25):1364–9. https://doi.org/10.1056/
NEJM197912203012503 PMID: 503167
2. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in can-
cer treatment: importance in quality of cancer care. J Clin Oncol. 2000; 18(11):2327–40. https://doi.org/
10.1200/JCO.2000.18.11.2327 PMID: 10829054
3. Killeen SD O’Sullivan MJ, Coffey JC, Kirwan WO, Redmond HP. Provider volume and outcomes for
oncological procedures. The British journal of surgery. 2005; 92(4):389–402. https://doi.org/10.1002/
bjs.4954
4. Dudley RA, Johansen KL, Brand R, Rennie DJ, Milstein A. Selective referral to high-volume hospitals:
estimating potentially avoidable deaths. Jama. 2000; 283(9):1159–66. PMID: 10703778
5. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and
methodologic critique of the literature. Ann Intern Med. 2002; 137(6):511–20. PMID: 12230353
6. van Heek NT, Kuhlmann KF, Scholten RJ, de Castro SM, Busch OR, van Gulik TM, et al. Hospital vol-
ume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in
Centralisation of cancer treatment
PLOS ONE | https://doi.org/10.1371/journal.pone.0195673 April 12, 2018 9 / 11
the Netherlands. Ann Surg. 2005; 242(6):781–8, discussion 8–90. https://doi.org/10.1097/01.sla.
0000188462.00249.36 PMID: 16327488
7. Ho VK, van der Heiden-van der Loo M, Rutgers EJ, van Diest PJ, Hobbelink MG, Tjan-Heijnen VC,
et al. Implementation of sentinel node biopsy in breast cancer patients in the Netherlands. European
journal of cancer. 2008; 44(5):683–91. https://doi.org/10.1016/j.ejca.2008.01.027 PMID: 18314328
8. Gouma DJ, van Geenen RC, van Gulik TM, de Haan RJ, de Wit LT, Busch OR, et al. Rates of complica-
tions and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann
Surg. 2000; 232(6):786–95. PMID: 11088073
9. van Lanschot JJ, Hulscher JB, Buskens CJ, Tilanus HW, ten Kate FJ, Obertop H. Hospital volume and
hospital mortality for esophagectomy. Cancer. 2001; 91(8):1574–8. PMID: 11301408
10. Gouma DJ, De Wit LT, Van Berge Henegouwen MI, Van Gulik TH, Obertop H. [Hospital experience and
hospital mortality following partial pancreaticoduodenectomy in The Netherlands]. Nederlands tijdschrift
voor geneeskunde. 1997; 141(36):1738–41. PMID: 9545716
11. Wouters MW, Karim-Kos HE, le Cessie S, Wijnhoven BP, Stassen LP, Steup WH, et al. Centralization
of esophageal cancer surgery: does it improve clinical outcome? Annals of surgical oncology. 2009; 16
(7):1789–98. https://doi.org/10.1245/s10434-009-0458-9 PMID: 19370377
12. Smolders KH, Den Ouden AL, Nugteren WA, Van Der Wal G. Does public disclosure of quality indica-
tors influence hospitals’ inclination to enhance results? Int J Qual Health Care. 2012; 24(2):129–34.
https://doi.org/10.1093/intqhc/mzs003 PMID: 22315017
13. Wouters MW, Jansen-Landheer ML, van de Velde CJ. The Quality of Cancer Care initiative in the Neth-
erlands. Eur J Surg Oncol. 2010; 36 Suppl 1:S3–S13.
14. Stichting Oncologische Samenwerking. Multidisciplinaire normering oncologische zorg Nederland.
2015. Available from: www.soncos.org
15. Elting LS, Pettaway C, Bekele BN, Grossman HB, Cooksley C, Avritscher EB, et al. Correlation
between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-
based study. Cancer. 2005; 104(5):975–84. https://doi.org/10.1002/cncr.21273 PMID: 16044400
16. Hollenbeck BK, Daignault S, Dunn RL, Gilbert S, Weizer AZ, Miller DC. Getting under the hood of the
volume-outcome relationship for radical cystectomy. The Journal of urology. 2007; 177(6):2095–9; dis-
cussion 9. https://doi.org/10.1016/j.juro.2007.01.153 PMID: 17509295
17. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and sur-
gical mortality in the United States. N Engl J Med. 2002; 346(15):1128–37. https://doi.org/10.1056/
NEJMsa012337 PMID: 11948273
18. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and
operative mortality in the United States. N Engl J Med. 2003; 349(22):2117–27. https://doi.org/10.1056/
NEJMsa035205 PMID: 14645640
19. Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of cancer regis-
tration in Limburg, The Netherlands. International journal of epidemiology. 1993; 22(3):369–76. PMID:
8359950
20. Schouten LJ, Jager JJ, van den Brandt PA. Quality of cancer registry data: a comparison of data pro-
vided by clinicians with those of registration personnel. British journal of cancer. 1993; 68(5):974–7.
PMID: 8217612
21. CBS Statistics Netherlands. 2015 [cited 2015 September 20th]. Available from: http://statline.cbs.nl/
StatWeb/publication/?VW=T&DM=SLNL&PA=37296ned&D1=a&D2=0,10,20,30,40,50,60,(l-1),l&HD=
130605-0924&HDR=G1&STB=T
22. de Vries RR, Visser O, Nieuwenhuijzen JA, Horenblas S, Members of the Urological Oncology Working
Group of the Comprehensive Cancer Centre A. Outcome of treatment of bladder cancer: a comparison
between low-volume hospitals and an oncology centre. World journal of urology. 2010; 28(4):431–7.
https://doi.org/10.1007/s00345-010-0512-z
23. Goossens-Laan CA, Visser O, Wouters MW, Jansen-Landheer ML, Coebergh JW, van de Velde CJ,
et al. Variations in treatment policies and outcome for bladder cancer in the Netherlands. Eur J Surg
Oncol. 2010; 36 Suppl 1:S100–7.
24. Goossens-Laan CA, Visser O, Hulshof MC, Wouters MW, Bosch JL, Coebergh JW, et al. Survival after
treatment for carcinoma invading bladder muscle: a Dutch population-based study on the impact of hos-
pital volume. BJU international. 2012; 110(2):226–32. https://doi.org/10.1111/j.1464-410X.2011.10694.
x PMID: 22044615
25. Dutch Society for Urology. Kwaliteitsnormen Blaascarcinoom. 2015 Januari 2015.
26. Billingsley KG, Morris AM, Dominitz JA, Matthews B, Dobie S, Barlow W, Wright GE, Baldwin L. Sur-
geon and Hospital Characteristics as Predictors of Major Adverse Outcomes Following Colon Cancer
Centralisation of cancer treatment
PLOS ONE | https://doi.org/10.1371/journal.pone.0195673 April 12, 2018 10 / 11
SurgeryUnderstanding the Volume-Outcome Relationship. Arch Surg. 2007; 142(1):23–31. https://doi.
org/10.1001/archsurg.142.1.23 PMID: 17224497
27. Liu C.-J., Chou Y.-J., Teng C.-J., Lin C.-C., Lee Y.-T., Hu Y.-W., Yeh C.-M., Chen T.-J. and Huang N.
(2015), Association of surgeon volume and hospital volume with the outcome of patients receiving defin-
itive surgery for colorectal cancer: A nationwide population-based study. Cancer, 121: 2782–2790.
https://doi.org/10.1002/cncr.29356 PMID: 25892632
28. Schrag D., Panageas K. S., Riedel E., Hsieh L., Bach P. B., Guillem J. G. and Begg C. B. (2003), Sur-
geon volume compared to hospital volume as a predictor of outcome following primary colon cancer
resection. J. Surg. Oncol., 83: 68–78. https://doi.org/10.1002/jso.10244 PMID: 12772198
Centralisation of cancer treatment
PLOS ONE | https://doi.org/10.1371/journal.pone.0195673 April 12, 2018 11 / 11
